Arrhythmias & electrophysiologyCohort study
Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)
- Single-arm phase III study
- prospective
- multicentre
- open-label
- uncontrolled
Authors' conclusion
Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported.
Study context
- Population
- Paediatric patients (≥1 day to <18 years) with supraventricular tachycardia (SVT) of various aetiologies, surgical and non-surgical settings, Europe
- Participants
- 60 patients
- Outcome
- Restoration of normal sinus rhythm (NSR)
- Follow-up
- Within 210 min of infusion start
Main finding
As reported in the abstract
Restoration of NSR within 210 min of infusion start · within 210 min
Primary endpoint achieved (normal sinus rhythm (NSR) restored)
15 (25.0%)
Observational data: associations, not effects.
Further findings
HR reduction ≥20% · within 210 min
- Patients achieving HR reduction of at least 20%
- 24 (40.0%)
HR reduction, overall population · after 210 min
- Mean (±SD) HR reduction
- −13.2 (±11.5)%
- P
- P < 0.0001
HR reduction ≥20% from baseline and/or NSR conversion · by infusion end
- Patients achieving HR reduction ≥20% and/or NSR conversion
- 51.7%
Safety
Hypotension (most common adverse drug reaction)
- Hypotension
- 10%
Original publication
Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED). Europace. Published 14 February 2025. doi:10.1093/europace/euaf025
Summarised from the published abstract; every number is checked against it